

Manjie Xing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10545861/publications.pdf>

Version: 2024-02-01

17
papers

880
citations

840776

11
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1910
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. <i>Cancer Cell</i> , 2018, 33, 137-150.e5.	16.8	175
2	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. <i>Nature Communications</i> , 2016, 7, 12983.	12.8	123
3	VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 1284-1305.	9.4	111
4	Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. <i>Nature Communications</i> , 2018, 9, 1520.	12.8	109
5	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. <i>Nature Communications</i> , 2014, 5, 4361.	12.8	72
6	Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 919-930.	21.4	65
7	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 630-651.	9.4	48
8	HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. <i>Nature Communications</i> , 2018, 9, 100.	12.8	38
9	Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. <i>Gut</i> , 2020, 69, 1039-1052.	12.1	36
10	HNF4 pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. <i>Gut</i> , 2020, 69, 231-242.	12.1	27
11	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	12.1	23
12	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3005-3020.	8.2	12
13	Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation. <i>Genome Biology</i> , 2021, 22, 167.	8.8	10
14	Epigenomic Consequences of Coding and Noncoding Driver Mutations. <i>Trends in Cancer</i> , 2016, 2, 585-605.	7.4	8
15	Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. <i>Genome Medicine</i> , 2021, 13, 158.	8.2	7
16	Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. <i>Cancer Research</i> , 2022, 82, 2538-2551.	0.9	7
17	Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. <i>Gut</i> , 2023, 72, 226-241.	12.1	6